EP1041989A4 - Novel cycloalkenyl substituted compounds - Google Patents

Novel cycloalkenyl substituted compounds

Info

Publication number
EP1041989A4
EP1041989A4 EP98953306A EP98953306A EP1041989A4 EP 1041989 A4 EP1041989 A4 EP 1041989A4 EP 98953306 A EP98953306 A EP 98953306A EP 98953306 A EP98953306 A EP 98953306A EP 1041989 A4 EP1041989 A4 EP 1041989A4
Authority
EP
European Patent Office
Prior art keywords
substituted compounds
cycloalkenyl substituted
novel
novel cycloalkenyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98953306A
Other languages
German (de)
French (fr)
Other versions
EP1041989A1 (en
Inventor
Jerry L Adams
Ravi Shanker Garigipati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1041989A1 publication Critical patent/EP1041989A1/en
Publication of EP1041989A4 publication Critical patent/EP1041989A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
EP98953306A 1997-10-08 1998-10-08 Novel cycloalkenyl substituted compounds Withdrawn EP1041989A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6135197P 1997-10-08 1997-10-08
US61351P 1997-10-08
PCT/US1998/021189 WO1999017776A1 (en) 1997-10-08 1998-10-08 Novel cycloalkenyl substituted compounds

Publications (2)

Publication Number Publication Date
EP1041989A1 EP1041989A1 (en) 2000-10-11
EP1041989A4 true EP1041989A4 (en) 2002-11-20

Family

ID=22035230

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98953306A Withdrawn EP1041989A4 (en) 1997-10-08 1998-10-08 Novel cycloalkenyl substituted compounds

Country Status (5)

Country Link
US (1) US6362193B1 (en)
EP (1) EP1041989A4 (en)
JP (1) JP2001518507A (en)
CA (1) CA2306077A1 (en)
WO (1) WO1999017776A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1041989A4 (en) 1997-10-08 2002-11-20 Smithkline Beecham Corp Novel cycloalkenyl substituted compounds
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2341370A1 (en) 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
EP1126852B1 (en) * 1998-11-04 2004-01-21 SmithKline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
JP2003528043A (en) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
DE60015599T2 (en) 1999-11-23 2005-11-03 Smithkline Beecham Corp. 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / p38 KINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003514900A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
IL155367A0 (en) * 2000-10-23 2003-12-23 Smithkline Beecham Corp NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
US7232821B2 (en) 2002-04-08 2007-06-19 Glaxo Group Limited (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
RU2253440C1 (en) * 2004-03-31 2005-06-10 Открытое Акционерное Общество "Фаберлик" Preparation for removing disorders of neurogenic and endocrine regulation in the system of capillary circulation
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
PE20100737A1 (en) 2005-03-25 2010-11-27 Glaxo Group Ltd NEW COMPOUNDS
EP1865959A2 (en) * 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
WO1995030652A1 (en) * 1994-05-04 1995-11-16 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
WO1996021654A1 (en) * 1995-01-12 1996-07-18 Smithkline Beecham Corporation Novel compounds
WO1996021452A1 (en) * 1995-01-09 1996-07-18 Smithkline Beecham Corporation Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
WO1997016435A1 (en) * 1995-10-30 1997-05-09 Merck Frosst Canada Inc. 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
WO1997032583A1 (en) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
WO1997035856A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
DD201677A5 (en) 1980-07-25 1983-08-03 Ciba Geigy PROCESS FOR THE PREPARATION OF TRISUBSTITUTED IMIDAZOLE DERIVATIVES
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US5663180A (en) 1983-10-29 1997-09-02 G.D. Searle & Co. Substituted cyclopentenes for the treatment of inflammation
US4565875A (en) 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
AU9169991A (en) 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
EP0565582A4 (en) 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids.
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5716972A (en) 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6008235A (en) 1992-01-13 1999-12-28 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
WO1995003297A1 (en) 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
JP3377529B2 (en) 1993-09-17 2003-02-17 スミスクライン・ビーチャム・コーポレイション Drug binding protein
JPH09505055A (en) 1993-11-08 1997-05-20 スミスクライン・ビーチャム・コーポレイション Oxazole for treatment of cytokine-mediated diseases
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL123950A (en) 1995-10-06 2001-04-30 Merck & Co Inc Substituted imidazoles having anti-cancer and cytokine inhibitory activity and pharmaceutical compositions containing them
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2000503302A (en) 1996-01-11 2000-03-21 スミスクライン・ビーチャム・コーポレイション New substituted imidazole compounds
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
EP0888335A4 (en) 1996-03-13 2002-01-02 Smithkline Beecham Corp Novel pyrimidine compounds useful in treating cytokine mediated diseases
EP0889887A4 (en) 1996-03-25 2003-06-11 Smithkline Beecham Corp Novel treatment for cns injuries
WO1997036587A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. A method of treating cancer
JP3418624B2 (en) 1996-06-10 2003-06-23 メルク エンド カンパニー インコーポレーテッド Substituted imidazoles having cytokine inhibitory activity
WO1998006751A1 (en) 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0956018A4 (en) 1996-08-21 2000-01-12 Smithkline Beecham Corp Imidazole compounds, compositions and use
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
US5929076A (en) 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
AU7138298A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
CA2295762A1 (en) 1997-07-02 1999-01-14 Ravi Shanker Garigipati Novel cycloalkyl substituted imidazoles
AR016294A1 (en) 1997-07-02 2001-07-04 Smithkline Beecham Corp IMIDAZOL SUBSTITUTE COMPOSITE, PHARMACEUTICAL COMPOSITION CONTAINING IT, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR SUPREPARATION
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
EP1041989A4 (en) 1997-10-08 2002-11-20 Smithkline Beecham Corp Novel cycloalkenyl substituted compounds
CA2316296A1 (en) 1997-10-10 1999-04-22 Imperial College Of Science, Technology And Medicine Use of csaidtm compounds for the management of uterine contractions
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
KR20010025087A (en) 1998-05-22 2001-03-26 스튜어트 알. 수터 Novel 2-Alkyl Substituted Imidazole Compounds
WO1999061440A1 (en) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5418254A (en) * 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
WO1995030652A1 (en) * 1994-05-04 1995-11-16 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
WO1996021452A1 (en) * 1995-01-09 1996-07-18 Smithkline Beecham Corporation Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine
WO1996021654A1 (en) * 1995-01-12 1996-07-18 Smithkline Beecham Corporation Novel compounds
WO1997016435A1 (en) * 1995-10-30 1997-05-09 Merck Frosst Canada Inc. 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
WO1997032583A1 (en) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
WO1997035856A1 (en) * 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9917776A1 *

Also Published As

Publication number Publication date
WO1999017776A1 (en) 1999-04-15
CA2306077A1 (en) 1999-04-15
US6362193B1 (en) 2002-03-26
EP1041989A1 (en) 2000-10-11
JP2001518507A (en) 2001-10-16

Similar Documents

Publication Publication Date Title
EP1041989A4 (en) Novel cycloalkenyl substituted compounds
EG24412A (en) Novel compounds
EG24177A (en) Novel compounds
GB9701684D0 (en) Novel compounds
GB9706255D0 (en) Novel compounds
GB9707830D0 (en) Novel compounds
GB9713732D0 (en) Substituted triazinic compounds
GB9703492D0 (en) Novel compounds
GB9700901D0 (en) Novel compounds
GB9709083D0 (en) Novel compounds
GB9703334D0 (en) Novel compounds
GB9705620D0 (en) Novel compounds
GB9703333D0 (en) Novel compounds
GB9705385D0 (en) Novel compounds
GB9706525D0 (en) Novel compounds
GB9703011D0 (en) Novel compounds
GB9706827D0 (en) Novel compounds
GB9704462D0 (en) Novel compounds
GB9706937D0 (en) Novel compounds
GB9707829D0 (en) Novel compounds
GB9701597D0 (en) Novel compounds
GB9700590D0 (en) Novel compounds
GB9700902D0 (en) Novel compounds
GB9712625D0 (en) Novel compounds
GB9704461D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20021008

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 217/02 A, 7A 61K 31/505 B, 7A 61K 31/53 B, 7A 61K 31/50 B, 7A 61K 31/47 B, 7A 61K 31/44 B, 7C 07D 239/02 B, 7C 07D 237/02 B, 7C 07D 243/34 B, 7C 07D 251/02 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021228